+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

P

Actively Recruiting

The trial investigates the effectiveness and safety of two dosing schedules of pegozafermin compared to a placebo in adults with metabolic dysfunction-associated steatohepatitis MASH who have liver fibrosis stages F2 or F3. This phase 3 study focuses on people aged 18 to 80 years and aims to better understand treatment options for this liver condition. Participants will be randomly assigned to receive one of two pegozafermin regimens or a matching placebo. Both pegozafermin and placebo are given by subcutaneous injection. The study includes a treatment period lasting up to 52 weeks, during which the effects of these regimens on liver fibrosis and steatohepatitis will be assessed. Throughout the study, participants will undergo various evaluations including liver biopsies, blood tests measuring liver enzymes and fibrosis markers, and monitoring for disease progression for up to five years. Researchers will track improvements in liver fibrosis, resolution of steatohepatitis, changes in liver enzyme levels, and fibrosis scores to assess the impact of the treatments.

Age: 18Years - 80YearsAll GendersPhase 3
370 locations
E

Actively Recruiting

Healthy Volunteer

Researchers are exploring how multi-cancer detection MCD tests might work as tools to screen for multiple cancers at once in adults aged 45 to 75 without cancer. The study aims to understand the performance of two different MCD tests compared to a control group and how patients and doctors handle both normal and abnormal test results. This feasibility study will inform future trials and help improve early cancer detection when treatment is most effective. Participants will be randomly assigned to one of three groups one group will undergo the Shield MCD test, another the Avantect MCD test, and the third will serve as a control group with blood collection only. Blood samples are collected at enrollment and again after one year. Participants at unblinded sites receive their test results, and those with abnormal findings follow up with their clinicians for further testing. After the active study period, participants are followed passively for up to 10 years. During the study, participants complete questionnaires and provide blood samples on schedule. Researchers collect medical record data and monitor participant adherence, diagnostic outcomes, anxiety related to testing, and the accuracy of the tests in predicting cancer origins. Primary outcomes include enrollment feasibility, questionnaire completion, blood sample provision, and follow-up retention. Secondary outcomes evaluate diagnostic resolution, complications, and psychological impact. This comprehensive approach helps assess the practical aspects of MCD testing and its potential role in cancer screening.

Age: 45Years - 75YearsAll GendersPhase Not Applicable
45 locations